Choosing the safest acute therapy during chronic migraine prophylactic treatment: pharmacokinetic and pharmacodynamic considerations

References

• Steiner TJ, Birbeck GL, Jensen RH, et al. Headache disorders are third cause of disability worldwide. J Headache Pain. 2015;16:58.
   PubMed Web of Science ®Google Scholar
• Weatherall MW. The diagnosis and treatment of chronic migraine. Ther Adv Chronic Dis. 2015;6:115–123.
   PubMed Web of Science ®Google Scholar
• Dodick D, Freitag F, Banks J, et al. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicentre, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Clin Ther. 2009;31:542–549.
   PubMed Web of Science ®Google Scholar
• Linde K, Rossnagel K. Propranolol for migraine prophylaxis. Cochrane Database Syst Rev. 2004;(2):CD003225.
   PubMedGoogle Scholar
• Diener H, Bussone G, Van Oene J, et al. Topiramate reduces headache days in chronic migraine: a randomised, double-blind, placebo-controlled study. Cephalalgia. 2007;27:814–823.
   PubMed Web of Science ®Google Scholar
• Silberstein S, Lipton R, Dodick D, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache. 2007;47:170–180.
   PubMed Web of Science ®Google Scholar
• Mulleners W, McCrory D, Linde M, Antiepileptics in migraine prophylaxis: an updated review. Cephalalgia. 2015;35:51–62.
   PubMed Web of Science ®Google Scholar
• Yurekli V, Akhan G, Kutluhan S, et al. The effect of sodium valproate on chronic daily headache and its subtypes. J Headache Pain. 2008;9:37–41.
   PubMed Web of Science ®Google Scholar
• Diener H, Matias-Guiu J, Hartung E, et al. Efficacy and tolerability in migraine prophylaxis of flunarizine in reduced doses: a comparison with propranolol 160 mg daily. Cephalalgia. 2002;22:209–221.
   PubMed Web of Science ®Google Scholar
• Kirthi V, Derry S, Moore RA, et al. Aspirin with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2010;4:CD008041.
   PubMed Web of Science ®Google Scholar
• Rabbie R, Derry S, Moore RA, et al. Ibuprofen with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2010;10:CD008039.
   PubMed Web of Science ®Google Scholar
• Derry S, Moore RA, McQuay HJ. Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2010;11:CD008040.
   PubMed Web of Science ®Google Scholar
• Magee KR, Westerberg MR, DeJong RM. Treatment of headache with ergotamine-caffeine suppositories. Neurology. 1952;2:477–480.
   PubMed Web of Science ®Google Scholar
• Andersson PG, Jespersen LT. Dihydroergotamine nasal spray in the treatment of attacks of cluster headaches. Cephalalgia. 1986;6:51–54.
   PubMed Web of Science ®Google Scholar
• Ferrari MD, Roon KI, Lipton RB, et al. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 2001;358:1668–1675.
   PubMed Web of Science ®Google Scholar
• Azzopardi TD, Brooks NA. Oral metoclopramide as an adjunct to analgesics for the outpatient treatment of acute migraine. Ann Pharmacother. 2008;42:397–402.
   PubMed Web of Science ®Google Scholar
• Winner P, Linder S, Hershey AD. Consistency of response to sumatriptan/naproxen sodium in a randomized placebo-controlled, cross-over study for the acute treatment of migraine in adolescence. Headache. 2015;55:519–528.
   PubMed Web of Science ®Google Scholar
• Sarchielli P, Granella F, Prudenzano MP, et al. Italian guidelines for primary headaches: 2012 revised version. J Headache Pain. 2012;13(Suppl 2):S31S70.
   Google Scholar
• Palleria C, Di Paolo A, Giofrè C, et al. Pharmacokinetic drug-drug interaction and their implication in clinical management. J Res Med Sci. 2013;18:601–610.
   PubMed Web of Science ®Google Scholar
• Johnell K, Klarin I. The relationship between number of drugs and potential drug-drug interactions in the elderly: a study of over 600,000 elderly patients from the Swedish Prescribed Drug Register. Drug Saf. 2007;30:911–918.
   PubMed Web of Science ®Google Scholar
• Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138:103–141.
   PubMed Web of Science ®Google Scholar
• Lin JH, Lu AY. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet. 1998;35:361–390.
   PubMed Web of Science ®Google Scholar
• [ cited 2015 Jul 29]. http://reference.medscape.com/drug-interactionchecker
   Google Scholar
• [ cited 2015 Jul 29]. http://www.drugbank.ca/
   Google Scholar
• Law V, Knox C, Djoumbou Y, et al. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res. 2014;42(1):D1091D1097. PubMed ID: 24203711
   Google Scholar
• [ cited 2015 Jul 29]. http://bioinformatics.charite.de/supercyp/
   Google Scholar
• Preissner S, Kroll K, Dunkel M, et al. SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010;38(Database issue):D237D243.
   Google Scholar
• http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm372273.htm
   Google Scholar
• Shamliyan TA, Choi JY, Ramakrishnan R, et al. Preventive pharmacologic treatments for episodic migraine in adults. J Gen Intern Med. 2013;28:1225–1237.
   PubMed Web of Science ®Google Scholar
• Schlondorff D. Renal complications of nonsteroidal anti-inflammatory drugs. Kidney Int. 1993;44:1062–1070.
   PubMed Web of Science ®Google Scholar
• Campbell WB, Gomez-Sanchez CE, Adams BV, et al. Attenuation of angiotensin II- and III-induced aldosterone release by prostaglandin synthesis inhibitors. J Clin Invest. 1979;64:1552.
   PubMed Web of Science ®Google Scholar
• Lim S. Approach to hyperkalemia. Acta Med Indones. 2007;39(2):99–103.
   PubMedGoogle Scholar
• Goldberg MR, Sciberras D, De Smet M, et al. Influence of beta-adrenoceptor antagonists on the pharmacokinetics of rizatriptan, a 5-HT1B/1D agonist: differential effects of propranolol, nadolol and metoprolol. Br J Clin Pharmacol. 2001;52:69–76.
   PubMed Web of Science ®Google Scholar
• Johnston MM, Rapoport AM. Triptans for the management of migraine. Drugs. 2010;70:1505–1518.
   PubMed Web of Science ®Google Scholar
• Gandy W. Dihydroergotamine interaction with propanalol. Ann Emerg Med. 1990;19:221.
   PubMed Web of Science ®Google Scholar
• Swen JJ, Nijenhuis M, De Boer A, et al. Pharmacogenetics: from bench to byte–an update of guidelines. Clin Pharmacol Ther. 2011;89:662–673.
   PubMed Web of Science ®Google Scholar
• Smitherman TA, Walters AB, Maizels M, et al. The use of antidepressants for headache prophylaxis. CNS Neurosci Ther. 2011;17:462–469.
   PubMed Web of Science ®Google Scholar
• Jackson JL, Cogbill E, Santana-Davila R, et al. A comparative effectiveness meta-analysis of drugs for the prophylaxis of migraine headache. PLoS One. 2015;10:e0130733.
   PubMed Web of Science ®Google Scholar
• Mathew NT, Tietjen GE, Lucker C. Serotonin syndrome complicating migraine pharmacotherapy. Cephalalgia. 1996;16:323–327.
   PubMed Web of Science ®Google Scholar
• Ramírez Rosas MB, Labruijere S, Villalón CM, et al. Activation of 5-hydroxytryptamine1B/1D/1F receptors as a mechanism of action of antimigraine drugs. Expert Opin Pharmacother. 2013;14:1599–1610.
   PubMed Web of Science ®Google Scholar
• Schiff PL. Ergot and its alkaloids. Am J Pharm Educ. 2006;70:98.
   PubMed Web of Science ®Google Scholar
• Gillman PK. Triptans, serotonin agonists, and serotonin syndrome (serotonin toxicity): a review. Headache. 2010;50(2):264–272.
   PubMed Web of Science ®Google Scholar
• Rolan PE. Drug interactions with triptans: which are clinically significant? CNS Drugs. 2012;26:949–957.
   PubMed Web of Science ®Google Scholar
• Bijl MJ, Visser LE, Hofman A, et al. Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants. Br J Clin Pharmacol. 2008;65:558–564.
   PubMed Web of Science ®Google Scholar
• Stingl JC, Brockmöller J. Personalised pharmacogenetics. Evidence-based guidelines and clinical application of pharmacogenetic diagnostics. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013;56:1509–1521.
   PubMed Web of Science ®Google Scholar
• Catterall WA. Sodium channels, inherited epilepsy, and antiepileptic drugs. Annu Rev Pharmacol Toxicol. 2014;54:317–338.
   PubMed Web of Science ®Google Scholar
• Farrell K, Orr JM, Abbott FS, et al. The effect of acetylsalicylic acid on serum free valproate concentrations and valproate clearance in children. J Pediatr. 1982;101:142–144.
   PubMed Web of Science ®Google Scholar
• Orr JM, Abbott FS, Farrell K, et al. Interaction between valproic acid and aspirin in epileptic children: serum protein binding and metabolic effects. Clin Pharmacol Ther. 1982;31:642–649.
   PubMed Web of Science ®Google Scholar
• Goulden KJ, Dooley JM, Camfield PR, et al. Clinical valproate toxicity induced by acetylsalicylic acid. Neurology. 1987;37:1392–1394.
   PubMed Web of Science ®Google Scholar
• Pisani F. Influence of co-medication on the metabolism of valproate. Pharm Weekbl Sci. 1992;14:108–113.
   PubMedGoogle Scholar
• Abbott FS, Kassam J, Orr JM, et al. The effect of aspirin on valproic acid metabolism. Clin Pharmacol Ther. 1986;40:94–10.
   PubMed Web of Science ®Google Scholar
• Sztajnkrycer MD. Valproic acid toxicity: overview and management. J Toxicol Clin Toxicol. 2002;40(6):789–801.
   PubMed Web of Science ®Google Scholar
• Munisamy M, Tripathi M, Behari M, et al. The effect of uridine diphosphate glucuronosyltransferase (UGT)1A6 genetic polymorphism on valproic acid pharmacokinetics in Indian patients with epilepsy: a pharmacogenetic approach. Mol Diagn Ther. 2013;17:319–326.
   PubMed Web of Science ®Google Scholar
• Krishnaswamy S, Hao Q, Al-Rohaimi A, et al. UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S). J Pharmacol Exp Ther. 2005;31:1340–1346.
   Web of Science ®Google Scholar
• Gunes A, Bilir E, Zengil H, et al. Inhibitory effect of valproic acid on cytochrome P450 2C9 activity in epilepsy patients. Basic Clin Pharmacol Toxicol. 2007;100:383–386.
   PubMed Web of Science ®Google Scholar
• Benedetti MS. Enzyme induction and inhibition by new antiepileptic drugs: a review of human studies. Fundam Clin Pharmacol. 2000;14:301–319.
   PubMed Web of Science ®Google Scholar
• Coen M. Metabolic phenotyping applied to pre-clinical and clinical studies of acetaminophen metabolism and hepatotoxicity. Drug Metab Rev. 2015;47:29–44.
   PubMed Web of Science ®Google Scholar
• Laine JE, Auriola S, Pasanen M, et al. Acetaminophen bioactivation by human cytochrome P450 enzymes and animal microsomes. Xenobiotica. 2009;39:11–21.
   PubMed Web of Science ®Google Scholar
• Cerveny L, Svecova L, Anzenbacherova E, et al. Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways. Drug Metab Dispos. 2007;35:1032–1041.
   PubMed Web of Science ®Google Scholar
• Hřebačková J, Poljaková J, Eckschlager T, et al. Histone deacetylase inhibitors valproate and trichostatin A are toxic to neuroblastoma cells and modulate cytochrome P450 1A1, 1B1 and 3A4 expression in these cells. Interdiscip Toxicol. 2009;2:205–210.
   PubMedGoogle Scholar
• Pourahmad J, Eskandari MR, Kaghazi A, et al. A new approach on valproic acid induced hepatotoxicity: involvement of lysosomal membrane leakiness and cellular proteolysis. Toxicol In Vitro. 2012;26:545–551.
   PubMed Web of Science ®Google Scholar
• Nallani SC, Glauser TA, Hariparsad N, et al. Dose-dependent induction of cytochrome P450 (CYP) 3A4 and activation of pregnane X receptor by topiramate. Epilepsia. 2003;44:1521–1528.
   PubMed Web of Science ®Google Scholar
• Lasso-de-la-Vega MC, Zapater P, Such J, et al. Gabapentin-associated hepatotoxicity. Am J Gastroenterol. 2001;96:3460–3462.
   PubMed Web of Science ®Google Scholar
• Taghdiri F, Togha M, Razeghi Jahromi S, et al. Cinnarizine for the prophylaxis of migraine associated vertigo: a retrospective study. SpringerPlus. 2014;3:231.
   PubMed Web of Science ®Google Scholar
• Schmidt R, Oestreich W. Flunarizine in migraine pro-phylaxis: the clinical experience. J Cardiovasc Pharmacol. 1991;18(Suppl 8):S21–S26.
   PubMed Web of Science ®Google Scholar
• Martınez-Lage JM. Flunarizine (Sibelium) in the prophylaxis of migraine. An open, long-term, multicenter trial. Cephalalgia Int J Headache. 1988;8(Suppl 8):15–20.
   PubMed Web of Science ®Google Scholar
• Kariya S, Isozaki S, Uchino K, et al. Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull. 1996;19:1511–1514.
   PubMed Web of Science ®Google Scholar